Primecap Management Co. CA cut its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR – Free Report) by 2.6% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 719,550 shares of the medical instruments supplier’s stock after selling 18,970 shares during the period. Primecap Management Co. CA owned approximately 0.97% of OraSure Technologies worth $3,065,000 as of its most recent SEC filing.
A number of other hedge funds also recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new stake in shares of OraSure Technologies during the first quarter worth approximately $72,000. Tocqueville Asset Management L.P. raised its position in OraSure Technologies by 20.0% during the 1st quarter. Tocqueville Asset Management L.P. now owns 15,089 shares of the medical instruments supplier’s stock worth $93,000 after buying an additional 2,512 shares during the last quarter. Shikiar Asset Management Inc. acquired a new stake in shares of OraSure Technologies in the 2nd quarter worth $96,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of OraSure Technologies in the fourth quarter valued at about $113,000. Finally, Tidal Investments LLC purchased a new stake in shares of OraSure Technologies in the first quarter valued at about $116,000. 93.50% of the stock is owned by institutional investors and hedge funds.
OraSure Technologies Price Performance
Shares of NASDAQ:OSUR opened at $4.31 on Thursday. OraSure Technologies, Inc. has a 12 month low of $3.91 and a 12 month high of $8.45. The firm has a market capitalization of $318.76 million, a price-to-earnings ratio of 14.37 and a beta of 0.05. The business’s 50 day simple moving average is $4.33 and its 200-day simple moving average is $4.98.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on OSUR shares. StockNews.com downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, August 17th. Evercore ISI lifted their price target on OraSure Technologies from $4.50 to $5.00 and gave the company an “in-line” rating in a research note on Wednesday, August 7th. Three equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $6.67.
View Our Latest Stock Report on OSUR
OraSure Technologies Profile
OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Further Reading
- Five stocks we like better than OraSure Technologies
- How to Effectively Use the MarketBeat Ratings Screener
- How Much Can You Make in Stocks in One Month?
- What is a Special Dividend?
- This Is the Top Large-Cap Stock Insiders Are Buying
- The 3 Best Retail Stocks to Shop for in August
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR – Free Report).
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.